Brief: Fusion Pharmaceuticals To Be Acquired By Astrazeneca, Accelerating Development Of Next-Generation Radioconjugates To Treat Cancer

Fusion Pharmaceuticals

19/03/2024 07:03

March 19 (Reuters) - Fusion Pharmaceuticals Inc
 FUSN.O :
    * FUSION PHARMACEUTICALS TO BE ACQUIRED BY ASTRAZENECA,
ACCELERATING DEVELOPMENT OF NEXT-GENERATION RADIOCONJUGATES TO
TREAT CANCER
    * REPRESENTING A TOTAL TRANSACTION VALUE OF APPROXIMATELY
$2.4
BILLION INCLUDING CVR
    * SHAREHOLDERS TO RECEIVE $21.00 PER SHARE IN CASH AT
CLOSING PLUS
A NON-TRANSFERRABLE CVR OF $3.00 PER SHARE
    * UPFRONT CASH PORTION OF CONSIDERATION REPRESENTS A
TRANSACTION
VALUE OF APPROXIMATELY $2 BILLION
    * FUSION WILL BECOME A WHOLLY OWNED SUBSIDIARY OF
ASTRAZENECA,
WITH OPERATIONS CONTINUING IN CANADA AND US

Source text for Eikon:  ID:nCNWTvFvKa 
Further company coverage:  FUSN.O 

 ((Reuters.Briefs@thomsonreuters.com;))